Introduction to Asia-Pacific Molecular Oncology Diagnostics Market
The Asia-Pacific molecular oncology diagnostics market was valued at $513.6 million in 2024, and the market is expected to grow with a CAGR of 12.99% and reach $1,542.0 million by 2033. Digital PCR, liquid biopsy, and next-generation sequencing (NGS) are the main technological factors propelling the APAC molecular cancer diagnostics market's explosive expansion. The need for earlier detection, more accurate therapy choices, and ultimately improved patient outcomes is being fuelled by the rising incidence of cancer in nations like China, India, and Japan.
However, a number of regional obstacles prevent wider implementation. In markets with smaller healthcare resources, especially in Southeast Asia, the high cost of advanced molecular diagnostics continues to be a significant barrier. Furthermore, in many areas of the region, there is a lack of qualified experts who can run sophisticated diagnostic systems and decipher massive amounts of genomic data.
The APAC market is still growing in spite of these obstacles. Innovation is being accelerated and molecular tools are being incorporated into routine oncology workflows through cooperative efforts between biotech businesses, pharmaceutical companies, diagnostic manufacturers, and academic institutions. Stakeholders must standardise reimbursement practices, reduce test costs through local and scaled production, and fund training initiatives to increase clinician genomic literacy across various healthcare systems if they are to fully realise the promise of precision cancer diagnostics.
Market Introduction
The market for molecular oncology diagnostics in Asia-Pacific (APAC) is expected to grow quickly as healthcare systems in China, India, Japan, and Southeast Asia place a greater emphasis on precision medicine. The use of molecular assays, especially next-generation sequencing (NGS), digital PCR, and liquid biopsy, is growing because they can more precisely and early identify genetic changes linked to cancer than conventional techniques. The demand for these cutting-edge instruments is being driven by the rising prevalence of colorectal, lung, and breast cancers as well as increased patient and physician awareness. Clinical adoption is also being accelerated by national genomics programs, companion diagnostics recommendations, and public and private investments in laboratory infrastructure. High test prices, disjointed regulatory procedures, and a lack of qualified bioinformaticians and molecular technologists, particularly in lower-income regions, continue to be major obstacles.
Industry participants are establishing strategic alliances, increasing locally produced goods, and putting in place training initiatives to develop technological know-how in order to overcome these obstacles. Automated high-throughput platforms are being implemented in the meanwhile to expedite processes and shorten turnaround times. In the future, the combination of AI-powered bioinformatics, increased reimbursement coverage, and more robust data-security frameworks will be essential for promoting long-term industry expansion. By providing more individualised, efficient cancer treatment in a variety of healthcare settings, the APAC molecular oncology diagnostics market is anticipated to take a sizable chunk of the worldwide precision oncology market by 2030.
Market Segmentation:
Segmentation 1: by Cancer Type
Solid Tumors
Hematologic Malignancies
Segmentation 2: by End User
Hospitals and Diagnostic Centers
Reference Laboratories
Pharmaceutical and Biotechnology Companies
Academic and Research Institutes
Segmentation 3: by Region
Asia-Pacific - Japan, China, India, South Korea, Australia, and Rest-of-Asia-Pacific
APAC Molecular Oncology Diagnostics Market Trends, Drivers & Challenges:
Market Trends
Technological Advancements: Rapid uptake of next generation sequencing (NGS), digital PCR and liquid biopsies (ctDNA/ctC) for non invasive, real time cancer monitoring.
Consolidation & Partnerships: Increased M&A activity reshaping the competitive landscape, with major lab and diagnostics players acquiring or partnering on advanced platforms.
Companion Diagnostics Integration: Growing adoption of CDx assays to match patients with targeted therapies, supported by evolving regulatory guidelines in key markets like Japan and Australia.
Automation & High Throughput Platforms: Deployment of automated systems in both clinical and research labs to boost efficiency and sample throughput.
Market Drivers
Rising Cancer Incidence: Surging rates of breast, lung and colorectal cancers across China, India, Japan and Southeast Asia fueling demand for precise diagnostics.
Precision Medicine Push: Strategic shift toward personalized oncology, with payers and providers investing in genotype-guided treatment pathways.
Government & Public-Private Initiatives: National programs and partnerships underwriting infrastructure expansion, including genomics missions and companion diagnostics guidelines.
Healthcare Infrastructure Investments: Capital inflows into lab upgrades, biotech R&D and specialized cancer centers enhancing regional capacity.
Market Challenges
High Cost of Testing: Advanced molecular assays remain expensive, limiting penetration in lower income APAC markets.
Regulatory Complexity: Fragmented and evolving approval pathways across different countries delay product launches.
Skilled Workforce Shortage: Insufficient numbers of trained molecular technologists and bioinformaticians impede broader clinical rollout.
Data Security & Privacy: Handling of sensitive genomic and patient data raises compliance and cybersecurity concerns.
*PDF email from publisher allows for 1-3 users, with permission to print*
Please Note: It will take 1-5 business days to complete the report upon order confirmation.
Executive Summary Scope and Definition 1 Molecular Oncology Diagnostics Market: Industry Outlook 1.1 Global Incidence and Prevalence of Cancer (by Cancer Type) 1.1.1 Asia-Pacific 1.2 Trends: Current and Future Impact Assessment 1.2.1 Increasing Partnerships among Players 1.2.2 Increasing Launch of Innovative Products and Regulatory Approvals in Molecular Oncology Diagnostics Ecosystem 1.3 Regulatory Landscape 1.3.1 Legal Requirements and Framework in Asia-Pacific 1.3.1.1 China 1.3.1.2 Japan 1.4 Impact of COVID-19 on the Molecular Oncology Diagnostics Market 1.5 Liquid Biopsy-Based Cancer Molecular Diagnostics 1.6 Laboratory-Developed Test (LDT) vs. In-Vitro Diagnostics (IVD) 1.7 Role of Companion Diagnostics in the Molecular Oncology Diagnostics Market 1.8 Market Dynamics 1.8.1 Market Drivers 1.8.1.1 Rising Incidence of Cancer Cases 1.8.1.2 Rising Technological Advancements in Molecular Diagnostics 1.8.1.3 Growth in Biomarker Identification and Transformations in Molecular Techniques 1.8.1.4 Growing Demand for Personalized Medicine 1.8.2 Market Challenges 1.8.2.1 Lack of Qualified Professionals 1.8.2.2 High Cost of Molecular Diagnostic Kits and Assays Hindering the Adoption Rate 1.8.3 Market Opportunities 1.8.3.1 Focus on Reimbursement and Medical Coverage for Molecular Oncology Diagnostics 1.8.3.2 Focus on Next-Generation Ultrasensitive Molecular Diagnostics 1.8.3.3 Increasing Growth Opportunities for Molecular Diagnostics Companies in Emerging Economies 2 Molecular Oncology Diagnostics Market: by Region 2.1 Regional Summary 2.2 Drivers and Restraints 2.3 Asia-Pacific 2.3.1 Regional Overview 2.3.2 Driving Factors for Market Growth 2.3.3 Factors Challenging the Market 2.3.4 By Cancer Type 2.3.5 By End User 2.3.6 China 2.3.6.1 By Cancer Type 2.3.6.2 By End User 2.3.7 India 2.3.7.1 By Cancer Type 2.3.7.2 By End User 2.3.8 Japan 2.3.8.1 By Cancer Type By End User 2.3.9 South Korea 2.3.9.1 By Cancer Type 2.3.9.2 By End User 2.3.10 Australia 2.3.10.1 By Cancer Type 2.3.10.2 By End User 2.3.11 Rest-of-Asia-Pacific 2.3.11.1 By Cancer Type 2.3.11.2 By End User 2.4 Rest-of-the-World 2.4.1 Regional Overview 2.4.2 Driving Factors for Market Growth 2.4.3 Factors Challenging the Market 2.4.4 By Cancer Type 2.4.5 By End User 3 Molecular Oncology Diagnostics Market - Competitive Benchmarking & Company Profiles 3.1 Company Profiles 3.1.1 Sysmex Corporation 3.1.1.1 Overview 3.1.1.2 Top Products 3.1.1.3 Top Competitors 3.1.1.4 Target Customers/End User 3.1.1.5 Key Personnel 3.1.1.6 Analyst View 4 Research Methodology 4.1 Data Sources 4.1.1 Primary Data Sources 4.1.2 Secondary Data Sources 4.1.3 Data Triangulation 4.2 Market Estimation and Forecast List of Figures Figure 1 Asia-Pacific Molecular Oncology Diagnostics Market, $Million, 2024, 2028, and 2033 Figure 2 Molecular Oncology Diagnostics Market (by Region), $Million, 2023, 2027, and 2033 Figure 3 Asia-Pacific Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2023, 2027, and 2033 Figure 4 Asia-Pacific Molecular Oncology Diagnostics Market (by End User), $Million, 2023, 2027, and 2033 Figure 5 Role of Diagnostics in Healthcare Figure 6 Cancer Prevalence and Incidence (by Cancer Type), in Million, Asia-Pacific, 2022 Figure 7 Workflow for Medical Device Regulations Figure 8 Technological Advances in Liquid Biopsy Analysis Figure 9 List of Some Liquid Biopsy-Based Available Tests Approved by FDA/CE-IVD Figure 10 Impact Analysis of Market Navigating Factors, 2022-2033 Figure 11 Global Distribution of Cases and Deaths (by Cancer Type), 2022 Figure 12 Global Incidence for Cancer Types, 2018-2022 Figure 13 China Molecular Oncology Diagnostics Market, $Million, 2023-2033 Figure 14 India Molecular Oncology Diagnostics Market, $Million, 2023-2033 Figure 15 Japan Molecular Oncology Diagnostics Market, $Million, 2023-2033 Figure 16 South Korea Molecular Oncology Diagnostics Market, $Million, 2023-2033 Figure 17 Australia Molecular Oncology Diagnostics Market, $Million, 2023-2033 Figure 18 Rest-of-Asia-Pacific Molecular Oncology Diagnostics Market, $Million, 2023-2033 Figure 19 Data Triangulation Figure 20 Top-Down and Bottom-Up Approach Figure 21 Assumptions and Limitations List of Tables Table 1: Market Snapshot Table 2: Key Trends, Impact Analysis Table 3: Molecular Oncology Diagnostics Market, Partnerships and Collaborations Table 4: Molecular Oncology Diagnostics Market, Product Launches and Regulatory Approvals Table 5: Prominent FDA-Approved Companion Diagnostics Table 6: Molecular Oncology Diagnostics Market, New Offerings Table 7: Biomarkers for Different Cancer Types Table 8: Significance of Different Biomarkers in Clinical Outcomes of Various Cancer Table 9: Cost of Liquid Biopsy-Based NGS Kits Table 10: Molecular Oncology Diagnostics Market, Reimbursement and Medical Coverage Table 11: Molecular Oncology Diagnostics Market (by Region), $Million, 2023-2033 Table 12: Asia-Pacific Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2023-2033 Table 13: Asia-Pacific Molecular Oncology Diagnostics Market, Cancer Type (by Solid Tumors), $Million, 2023-2033 Table 14: Asia-Pacific Molecular Oncology Diagnostics Market, Cancer Type (by Hematological Malignancies), $Million, 2023-2033 Table 15: Asia-Pacific Molecular Oncology Diagnostics Market (by End User), $Million, 2023-2033 Table 16: China Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2023-2033 Table 17: China Molecular Oncology Diagnostics Market, Cancer Type (by Solid Tumors), $Million, 2023-2033 Table 18: China Molecular Oncology Diagnostics Market, Cancer Type (by Hematological Malignancies), $Million, 2023-2033 Table 19: China Molecular Oncology Diagnostics Market (by End User), $Million, 2023-2033 Table 20: India Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2023-2033 Table 21: India Molecular Oncology Diagnostics Market, Cancer Type (by Solid Tumors), $Million, 2023-2033 Table 22: India Molecular Oncology Diagnostics Market, Cancer Type (by Hematological Malignancies), $Million, 2023-2033 Table 23: India Molecular Oncology Diagnostics Market (by End User), $Million, 2023-2033 Table 24: Japan Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2023-2033 Table 25: Japan Molecular Oncology Diagnostics Market, Cancer Type (by Solid Tumors), $Million, 2023-2033 Table 26: Japan Molecular Oncology Diagnostics Market, Cancer Type (by Hematological Malignancies), $Million, 2023-2033 Table 27: Japan Molecular Oncology Diagnostics Market (by End User), $Million, 2023-2033 Table 28: South Korea Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2023-2033 Table 29: South Korea Molecular Oncology Diagnostics Market, Cancer Type (by Solid Tumors), $Million, 2023-2033 Table 30: South Korea Molecular Oncology Diagnostics Market, Cancer Type (by Hematological Malignancies), $Million, 2023-2033 Table 31: South Korea Molecular Oncology Diagnostics Market (by End User), $Million, 2023-2033 Table 32: Australia Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2023-2033 Table 33: Australia Molecular Oncology Diagnostics Market, Cancer Type (by Solid Tumors), $Million, 2023-2033 Table 34: Australia Molecular Oncology Diagnostics Market, Cancer Type (by Hematological Malignancies), $Million, 2023-2033 Table 35: Australia Molecular Oncology Diagnostics Market (by End User), $Million, 2023-2033 Table 36: Rest-of-Asia-Pacific Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2023-2033 Table 37: Rest-of-Asia-Pacific Molecular Oncology Diagnostics Market, Cancer Type (by Solid Tumors), $Million, 2023-2033 Table 38: Rest-of-Asia-Pacific Molecular Oncology Diagnostics Market, Cancer Type (by Hematological Malignancies), $Million, 2023-2033 Table 39: Rest-of-Asia-Pacific Molecular Oncology Diagnostics Market (by End User), $Million, 2023-2033
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook